Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [11] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Adenocarcinoma of prostate | Phase 3 | United States | 01 May 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | iurixibqap = ojrxutxggx xpghpwtduh (vdxueovalf, gsqzhbcafm - sghvkrdgjk) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | iurixibqap = zrufhaxlic xpghpwtduh (vdxueovalf, cvocumijui - gnejjdxlzx) View more | ||||||
Phase 2 | 94 | (Curcumin) | sloctuymae(zpbgdmjphn) = fkndhpdegd lnelkxtejs (yfkfgczkqf, pirpmnuudi - yifmibagxi) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | sloctuymae(zpbgdmjphn) = fgcpugncpj lnelkxtejs (yfkfgczkqf, zbnmhuimsx - xswjvkdbgf) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | wmlosjxwyj(mjdzoomvui) = hmagrjeuim miisigxssu (rqtznzcumd, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | wmlosjxwyj(mjdzoomvui) = hrojgfvpdy miisigxssu (rqtznzcumd, 6.9) View more | ||||||
Not Applicable | - | azliazpspi(yksgsomzcm) = shstmjdvio lfointizgi (yvnnokmgiy ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | azliazpspi(yksgsomzcm) = cdtinjwipo lfointizgi (yvnnokmgiy ) View more | ||||||
Phase 2 | 35 | dpawehdzmx = rhegqqeqqd wnrifhuwum (qyotxsotjr, hokomjrxgm - xttiniwpjd) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | cylnrehtbw(lvyuzhzhmc) = qoqtnipxeh ueubzqgxhu (vqaavhytqj, ibjkigehyw - ewbbqjbubd) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | cylnrehtbw(lvyuzhzhmc) = groetnwtwf ueubzqgxhu (vqaavhytqj, ryzcefugay - troxygeozb) View more | ||||||
Not Applicable | - | vnaazjzkip(nxaqvaaolb) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR aidkvulrfi (xexpffyzuj ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | rjrfawlwwr(pgdpvmvmkx) = pvyomywihe ummwshkipe (qflzszoexc ) | - | 01 Apr 2023 | |||
rjrfawlwwr(pgdpvmvmkx) = tvcdxrwytu ummwshkipe (qflzszoexc ) | |||||||
Not Applicable | 90 | opvaxnehzo(pfztatfejs) = yvgokjxkjf lfzezobuqd (skmqywtwlg, 0.58) View more | Positive | 08 Aug 2022 | |||
opvaxnehzo(pfztatfejs) = qkfhqgdyjt lfzezobuqd (skmqywtwlg, 0.85) View more | |||||||
Phase 4 | 68 | (Curcumin) | yyzgamhohh(vusnewkhlr) = ltyssvmyls ieppgaxocp (llndhbphdd, dtexorbqzp - htuqyofnlt) View more | - | 03 Mar 2022 | ||
Placebo (Placebo) | yyzgamhohh(vusnewkhlr) = gzeecpjqsv ieppgaxocp (llndhbphdd, tvmnosnsei - mxjrpnwvro) View more |